研究者一覧

石黒　智之Ishiguro Tomoyuki

■所属部署名	腫瘍内科
■職名	助教(医科)

Last Updated :2025/04/01

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody., Murayama Masakazu;Hosonuma Masahiro;Kuramasu Atsuo;Kobayashi Sei;Sasaki Akiko;Baba Yuta;Narikawa Yoichiro;Toyoda Hitoshi;Isobe Junya;Funayama Eiji;Tajima Kohei;Sasaki Aya;Maruyama Yuki;Yamazaki Yoshitaka;Shida Midori;Hamada Kazuyuki;Hirasawa Yuya;Tsurui Toshiaki;Ariizumi Hirotsugu;Ishiguro Tomoyuki;Suzuki Risako;Ohkuma Ryotaro;Kubota Yutaro;Horiike Atsushi;Sambe Takehiko;Tsuji Mayumi;Wada Satoshi;Kobayashi Shinichi;Shimane Toshikazu;Tsunoda Takuya;Kobayashi Hitome;Kiuchi Yuji;Yoshimura Kiyoshi, Scientific reports, 14(1), 2024年05月, 原著, 査読あり

Maximum Efficacy of Immune Checkpoint Inhibitors Occurs in Esophageal Cancer Patients With a Low Neutrophil-to-Lymphocyte Ratio and Good Performance Status Prior to Treatment., Hirasawa Yuya;Kubota Yutaro;Mura Emiko;Suzuki Risako;Tsurui Toshiaki;Iriguchi Nana;Ishiguro Tomoyuki;Ohkuma Ryotaro;Shimokawa Masahiro;Ariizumi Hirotsugu;Horiike Atsushi;Wada Satoshi;Ariyoshi Tomotake;Goto Satoru;Otsuka Koji;Murakami Masahiko;Kiuchi Yuji;Yoshimura Kiyoshi;Hoffman Robert M;Tsunoda Takuya, Anticancer research, 44(8):3397 - 3407, 2024年, 原著, 査読あり

Novel quantitative immunohistochemical analysis for evaluating PD-L1 expression with phosphor-integrated dots for predicting the efficacy of patients with cancer treated with immune checkpoint inhibitors., Ohkuma R, Miura S, Muto S, Toyomasu Y, Fujimoto Y, Ieguchi K, Onishi N, Shimizu T, Watanabe M, Takayanagi D, Goshima T, Horiike A, Hamada K, Ariizumi H, Shimokawa M, Hirasawa Y, Ishiguro T, Suzuki R, Iriguchi N, Tsurui T, Mura E, Takenoshita S, Numajiri K, Okabe N, Yoshimura K, Tsuji M, Kiuchi Y, Yajima T, Ishida H, Suzuki H, Yamochi T, Kobayashi S, Tsunoda T, Wada S., Front Immunol, 14:1260492, 2023年09月, 原著, 査読あり, DOI:10.3389/fimmu.2023.1260492

Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor., Kazuyuki Hamada, Junya Isobe, Kouya Hattori, Masahiro Hosonuma, Yuta Baba, Masakazu Murayama, Yoichiro Narikawa, Hitoshi Toyoda, Eiji Funayama, Kohei Tajima, Midori Shida, Yuya Hirasawa, Toshiaki Tsurui, Hirotsugu Ariizumi, Tomoyuki Ishiguro, Risako Suzuki, Ryotaro Ohkuma, Yutaro Kubota, Takehiko Sambe, Mayumi Tsuji, Satoshi Wada, Yuji Kiuchi, Shinichi Kobayashi, Atsuo Kuramasu, Atsushi Horiike, Yun-Gi Kim, Takuya Tsunoda and Kiyoshi Yoshimura, Front Immunol., 14:1164724, 2023年05月, 原著, 査読あり, DOI:10.3389/fimmu.2023.1164724

Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure., TSUBOYA Ayako;KUBOTA Yutaro;ISHIDA Hiroo;OHKUMA Ryotaro;ISHIGURO Tomoyuki;HIRASAWA Yuya;ARIIZUMI Hirotsugu;TSUNODA Takuya;SASAKI Yasutsuna;MATSUMOTO Natsumi;KONDO Yusuke;TOMODA Yukana;KUSUHARA Hiroyuki;FUJITA Ken-ichi, Cancer Chemother Pharmacol, :e, 2021年06月, 原著, 査読あり

The Prognostic Impact of Eosinophils and the Eosinophil-to-Lymphocyte Ratio on Survival Outcomes in Stage II Resectable Pancreatic Cancer., Ohkuma Ryotaro;Kubota Yutaro;Horiike Atsushi;Ishiguro Tomoyuki;Hirasawa Yuya;Ariizumi Hirotsugu;Watanabe Makoto;Onoue Rie;Ando Kiyohiro;Tsurutani Junji;Yoshimura Kiyoshi;Aoki Takeshi;Murakami Masahiko;Kobayashi Shinichi;Tsunoda Takuya;Wada Satoshi, Pancreas, 50(2), 2021年, 原著, 査読あり

Rare Nivolumab-associated Super Hyper Progressive Disease in Patients With Advanced Gastric Cancer., Kubota Yutaro;Yoshimura Kiyoshi;Hamada Kazuyuki;Hirasawa Yuya;Shida Midori;Taniguchi Makoto;Matsui Hiroto;Ariizumi Hirotsugu;Ishiguro Tomoyuki;Suzuki Norihiro;Ohkuma Ryotaro;Sambe Takehiko;Ishida Hiroo;Horiike Atsushi;Wada Satoshi;Tsurutani Junji;Iwamoto Sanju;Uchida Naoki;Kiuchi Yuji;Kobayashi Shinichi;Tsunoda Takuya, In vivo (Athens, Greece), 35(3), 2021年, 原著, 査読あり

A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy., Hirasawa Yuya;Yoshimura Kiyoshi;Matsui Hiroto;Kubota Yutaro;Ishida Hiroo;Arai Jun;Sakaki Masashi;Oguro Nao;Shida Midori;Taniguchi Makoto;Hamada Kazuyuki;Ariizumi Hirotsugu;Ishiguro Tomoyuki;Ohkuma Ryotaro;Sambe Takehiko;Horiike Atsushi;Imamura Chiyo K;Shiozawa Eisuke;Wada Satoshi;Tsurutani Junji;Iwamoto Sanju;Uchida Naoki;Kiuchi Yuji;Tate Genshu;Kobayashi Shinichi;Tsunoda Takuya, Medicine, 100(23), 2021年, 原著, 査読あり

A high number of PD-L1+ CD14+ monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors., Ando Kiyohiro;Hamada Kazuyuki;Shida Midori;Ohkuma Ryotaro;Kubota Yutaro;Horiike Atsushi;Matsui Hiroto;Ishiguro Tomoyuki;Hirasawa Yuya;Ariizumi Hirotsugu;Watanabe Makoto;Onoue Rie;Tsurutani Junji;Yoshimura Kiyoshi;Tsunoda Takuya;Kobayashi Shinichi;Wada Satoshi, Cancer immunology, immunotherapy : CII, 70(2), 2020年08月, 原著, 査読あり

Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients, MATSUMOTO Natsumi;KUBOTA Yutaro;ISHIDA Hiroo;SEKIDO Masae;OHKUMA Ryotaro;ISHIGURO Tomoyuki;HIRASAWA Yuya;ARIIZUMI Hirotsugu;TSUNODA Takuya;IKUSUE Toshikazu;KOBAYASHI Kouji;HISAMATSU Atsushi;TOSHIMA Hirokazu;SHIMADA Ken;FUJITA Ken-ichi, Cancer Chemother Pharmacol, 85(6):1119 - 1128, 2020年06月, 原著, 査読あり

Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors, ANDO Kiyohiro;HAMADA Kazuyuki;WATANABE Makoto;OHKUMA Ryotaro;SHIDA Midori;ONOUE Rie;KUBOTA Yutaro;MATSUI Hiroto;ISHIGURO Tomoyuki;HIRASAWA Yuya;ARIIZUMI Hirotsugu;TSURUTANI Junji;YOSHIMURA Kiyoshi;TSUNODA Takuya;KOBAYASHI Shinichi;WADA Satoshi, Anticancer Res, 39(9):5195 - 5201, 2019年09月, 原著, 査読あり

腎癌および尿路上皮癌患者におけるバイオマーカー探索のための腸内細菌叢の研究, 下山　英明;直江　道夫;サト　プラサド　ネパール;平松　綾;松井　祐輝;鵜木　勉;中里　武彦;押野見　和彦;森田　順;前田　佳子;冨士　幸藏;小川　良雄;角田　卓也;吉村　清, 昭和学士会雑誌, 79(4):492 - 504, 2019年08月, 原著, 査読あり